Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-11-16
pubmed:abstractText
Cancer stem cells/initiating cells (CSC/CIC), are thought to exist as a small population in malignant tissues. They are resistant to conventional cancer treatments and possibly underlie post-treatment relapse. The CIC population can be targeted with capsid modified oncolytic adenoviruses.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1932-6203
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e13859
pubmed:meshHeading
pubmed-meshheading:21079774-Adenoviridae, pubmed-meshheading:21079774-Antigens, CD24, pubmed-meshheading:21079774-Antigens, CD44, pubmed-meshheading:21079774-Blotting, Western, pubmed-meshheading:21079774-Breast Neoplasms, pubmed-meshheading:21079774-Cell Line, Tumor, pubmed-meshheading:21079774-Female, pubmed-meshheading:21079774-Host-Pathogen Interactions, pubmed-meshheading:21079774-Humans, pubmed-meshheading:21079774-Immune Tolerance, pubmed-meshheading:21079774-Immunity, Innate, pubmed-meshheading:21079774-Interferon Type I, pubmed-meshheading:21079774-Luminescent Proteins, pubmed-meshheading:21079774-Microscopy, Confocal, pubmed-meshheading:21079774-Myeloid Differentiation Factor 88, pubmed-meshheading:21079774-Neoplastic Stem Cells, pubmed-meshheading:21079774-Oncolytic Viruses, pubmed-meshheading:21079774-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:21079774-STAT1 Transcription Factor, pubmed-meshheading:21079774-STAT3 Transcription Factor, pubmed-meshheading:21079774-Suppressor of Cytokine Signaling Proteins, pubmed-meshheading:21079774-Toll-Like Receptor 2, pubmed-meshheading:21079774-Toll-Like Receptor 9
pubmed:year
2010
pubmed:articleTitle
Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.
pubmed:affiliation
Transplantation Laboratory, Cancer Gene Therapy Group, Molecular Cancer Biology Program, Haartman Institute, University of Helsinki, Helsinki, Finland. laura.ahtiainen@helsinki.fi
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't